placeholder image
J. E. Gray All authors
About
Publications While At HealthPartners
Highlights
selected publications
Journal Article
  • Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC; SWOG S1507, NCT-02642042). 
    Clinical Cancer Research. 2023
  • Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. 
    Lancet Oncology. 2018
  • Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. 
    New England Journal of Medicine. 2018
  • Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. 
    New England Journal of Medicine. 2017
    • Contact
    full name
  • J. E. Gray
    • Quick Info
    Publications
    Publications in the past 10 years based solely on publications while at HealthPartners. Publications in prior years appear in grey.
    Collaboration